151 related articles for article (PubMed ID: 15544995)
1. [Fluorinated analogs of nucleosides and fluorinated tracers of gene expression for positron emission tomography].
Couturier O; Chatal JF; Hustinx R
Bull Cancer; 2004 Sep; 91(9):695-703. PubMed ID: 15544995
[TBL] [Abstract][Full Text] [Related]
2. Fluorinated tracers for imaging cancer with positron emission tomography.
Couturier O; Luxen A; Chatal JF; Vuillez JP; Rigo P; Hustinx R
Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1182-206. PubMed ID: 15241631
[TBL] [Abstract][Full Text] [Related]
3. (18)F-labeled positron emission tomographic radiopharmaceuticals in oncology: an overview of radiochemistry and mechanisms of tumor localization.
Vallabhajosula S
Semin Nucl Med; 2007 Nov; 37(6):400-19. PubMed ID: 17920348
[TBL] [Abstract][Full Text] [Related]
4. [Fluorine-18 in radiopharmacy].
de Beco V; Le Bars D; Scherrmann JM
Ann Pharm Fr; 2008 Jan; 66(1):60-5. PubMed ID: 18435989
[TBL] [Abstract][Full Text] [Related]
5. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
[TBL] [Abstract][Full Text] [Related]
6. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography.
Barthel H; Cleij MC; Collingridge DR; Hutchinson OC; Osman S; He Q; Luthra SK; Brady F; Price PM; Aboagye EO
Cancer Res; 2003 Jul; 63(13):3791-8. PubMed ID: 12839975
[TBL] [Abstract][Full Text] [Related]
7. FDG and Beyond.
De Ruysscher D; Haustermans K; Thorwarth D
Recent Results Cancer Res; 2016; 198():163-73. PubMed ID: 27318686
[TBL] [Abstract][Full Text] [Related]
8. Fluorinated amino acids for tumour imaging with positron emission tomography.
Laverman P; Boerman OC; Corstens FH; Oyen WJ
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):681-90. PubMed ID: 11976809
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic use of fluorinated nucleosides - progress in patents.
Bassetto M; Slusarczyk M
Pharm Pat Anal; 2018 Nov; 7(6):277-299. PubMed ID: 30657414
[TBL] [Abstract][Full Text] [Related]
10. [Correlation of 3'-deoxy-3'-18F-fluorothymidine uptake to cell proliferation in lung carcinoma xenografts].
Liu X; Zhou NK; Zhang JM; Liang ZY; Zheng X
Ai Zheng; 2006 Dec; 25(12):1512-6. PubMed ID: 17166377
[TBL] [Abstract][Full Text] [Related]
11. Fluorine-18 radiopharmaceuticals beyond [18F]FDG for use in oncology and neurosciences.
Coenen HH; Elsinga PH; Iwata R; Kilbourn MR; Pillai MR; Rajan MG; Wagner HN; Zaknun JJ
Nucl Med Biol; 2010 Oct; 37(7):727-40. PubMed ID: 20870148
[TBL] [Abstract][Full Text] [Related]
12. Proliferation imaging with ¹⁸F-fluorothymidine PET/computed tomography: physiologic uptake, variants, and pitfalls.
Herrmann K; Buck AK
PET Clin; 2014 Jul; 9(3):331-8. PubMed ID: 25030396
[TBL] [Abstract][Full Text] [Related]
13. PET tracers in musculoskeletal disease beyond FDG.
Wieder HA; Pomykala KL; Benz MR; Buck AK; Herrmann K
Semin Musculoskelet Radiol; 2014 Apr; 18(2):123-32. PubMed ID: 24715445
[TBL] [Abstract][Full Text] [Related]
14. Update on PET radiopharmaceuticals: life beyond fluorodeoxyglucose.
Shiue CY; Welch MJ
Radiol Clin North Am; 2004 Nov; 42(6):1033-53, viii. PubMed ID: 15488556
[TBL] [Abstract][Full Text] [Related]
15. [Evaluation of therapies in oncology by positron emission tomography: towards therapeutical personalization].
Bonardel G; Vedrine L; Aupee O; Gontier E; Le Garlantezec P; Soret M; Foehrenbach H
Bull Cancer; 2009 Feb; 96(2):213-26. PubMed ID: 19258228
[TBL] [Abstract][Full Text] [Related]
16. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
[TBL] [Abstract][Full Text] [Related]
17. Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus.
Mullerad M; Eisenberg DP; Akhurst TJ; Adusumilli PS; Riedl CC; Bhargava A; Gonen M; Finn R; Scardino PT; Fong Y
Mol Imaging Biol; 2006; 8(1):30-5. PubMed ID: 16362150
[TBL] [Abstract][Full Text] [Related]
18. Oncologic PET tracers beyond [(18)F]FDG and the novel quantitative approaches in PET imaging.
Kumar R; Dhanpathi H; Basu S; Rubello D; Fanti S; Alavi A
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):50-65. PubMed ID: 18235421
[TBL] [Abstract][Full Text] [Related]
19. Potential clinical utility of dual time point FDG-PET for distinguishing benign from malignant lesions: implications for oncological imaging.
Sanz-Viedma S; Torigian DA; Parsons M; Basu S; Alavi A
Rev Esp Med Nucl; 2009; 28(3):159-66. PubMed ID: 19558958
[No Abstract] [Full Text] [Related]
20. Imaging of tumour hypoxia using PET and 18F-labelled tracers: biology meets technology.
Grönroos T; Minn H
Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1563-5. PubMed ID: 17598110
[No Abstract] [Full Text] [Related]
[Next] [New Search]
